• Roscovitine (Seliciclib) in CDK Assays

  2026-08-31

  Roscovitine (Seliciclib, CYC202) gives cancer biology research a practical way to connect CDK inhibition with reversible cell-cycle phenotypes. This workflow combines dose–response design, orthogonal late-prophase readouts, and data-driven compound-selection principles to improve assay interpretability.

• EdU Imaging Kits for S-Phase Proliferation

  2026-08-31

  EdU Imaging Kits (HF488) convert newly synthesized DNA into a quantifiable fluorescence signal for microscopy or flow cytometry. This article shows how to apply the assay to drug-response studies such as TRIB3 knockdown and sunitinib treatment, while separating reduced proliferation from cell death.

• SFI Inhibits Glioma via SRC/PI3K/AKT

  2026-08-30

  This 2024 study integrates network pharmacology with cellular and mouse experiments to explain how Shenqi Fuzheng injection suppresses glioma proliferation and migration. Its principal contribution is linking the observed anti-glioma effects to modulation of the SRC/PI3K/AKT pathway while identifying experimental readouts that can guide mechanistic validation.

• Biotin-HPDP for Reversible Thiol Labeling

  2026-08-29

  Biotin-HPDP combines selective cysteine chemistry with a cleavable biotin handle, making it useful for thiol enrichment, S-nitrosylation studies, and affinity workflows. Its application to TRPV1 palmitoylation provides a practical bridge between redox biochemistry, membrane-protein analysis, and pain neuroscience.

• Beyond Viability: A Translational Strategy for (+)-JQ1

  2026-08-28

  A mechanistic and strategic guide to using (+)-JQ1 as a BET bromodomain inhibitor, with emphasis on assay design, apoptosis interpretation, cross-domain translation, and research limitations.

• Exosomal SNORD52 Activates JAK2/STAT6 in HCC

  2026-08-28

  The reference study identifies hepatoma cell-derived exosomal SNORD52 as a transferable non-coding RNA signal that promotes M2 macrophage polarization through JAK2/STAT6 activation. Its experimental framework connects tumor-cell RNA cargo, macrophage phenotype, and signaling proteins, offering a mechanistic basis for studying immune remodeling in hepatocellular carcinoma.

• CXCR4–EGFR Heteromers Reshape Signaling

  2026-08-27

  Comez et al. show that CXCR4 and EGFR form signaling-competent oligomeric complexes whose conformation and Gi-protein coupling change after receptor stimulation. By combining NanoBRET with nanobody-based proximity ligation assays, the study connects receptor proximity in engineered cells with endogenous CXCR4–EGFR complexes in HeLa cells.

• Cefoperazone Sodium Salt: Assay Workflows

  2026-08-27

  Build reproducible Cefoperazone susceptibility, bactericidal, and resistance-mechanism workflows with controlled stock preparation and organism-stratified readouts. The approach connects β-lactamase stability, gram-negative screening, and biliary tract infection research without confusing in vitro performance with clinical efficacy.

• ATF4 and DNA Repair in CUX2+ Cortical Neurons

  2026-08-26

  The reference study identifies ATF4 as a developmental DNA-damage-response regulator that protects embryonic cortical progenitors and is particularly important for the expansion of CUX2-positive upper-layer neurons. Its results connect replicative stress, CIRBP-dependent ATM signaling, p53-mediated cell death, and the evolutionary growth of the mammalian outer cortex.

• Naringenin, ER Stress, and HCV-Linked Insulin Resistance

  2026-08-26

  The reference study identifies the IRE1α–XBP1s arm of the unfolded protein response as a mechanistic link between HCV core protein activity, hepatic endoplasmic reticulum stress, and insulin resistance. Its model-based evidence indicates that naringenin improves insulin sensitivity by suppressing this pathway, while tunicamycin provides a useful experimental comparator for ER-stress modulation.

• Fluorescein Tyramide for Sensitive Neural Assays

  2026-08-25

  Fluorescein Tyramide converts weak enzyme-linked signals into bright, spatially confined fluorescence for low-abundance targets in neural tissue. This guide translates recent oxytocin-circuit findings into practical IHC, ISH, multiplex, and exploratory flow-cytometry workflows, with optimization conditions and troubleshooting guidance.

• Ceftolozane/Tazobactam: Evidence, Methods, and Limits

  2026-08-25

  Cho, Fiorenza, and Estrada’s review analyzes why ceftolozane/tazobactam was developed as an antipseudomonal cephalosporin–β-lactamase inhibitor combination and synthesizes its mechanism, pharmacology, susceptibility profile, clinical evidence, and safety. Its practical contribution is a framework for interpreting PBP activity, β-lactamase coverage, time above MIC, renal clearance, and the limits of translating in vitro activity into treatment decisions.

• BMS-777607: Designing Better MET and MK Assays

  2026-08-24

  Explore how BMS-777607, a selective c-Met inhibitor, can sharpen mechanistic studies of MET signaling, tumor dissemination, and megakaryocyte maturation. This article connects validated kinase pharmacology with the assay-design lessons of optimized hiPSC-derived platelet production while clearly separating evidence from hypothesis.

• FK866 (APO866) Experimental Workflows

  2026-08-24

  Build reproducible NAD-depletion assays with FK866 (APO866), from concentration finding through mitochondrial and autophagy readouts. Its value extends beyond generic viability testing: the compound enables mechanism-led hematologic cancer research and hypothesis-driven studies of NAD-linked therapy resistance.

• UTP and the Logic of Olfactory RNA Precision

  2026-08-23

  A translational perspective on how UTP quality, RNA synthesis control, and TRIM66-mediated enhancer repression can be integrated into more reproducible olfactory neuroscience workflows.

8031 records 1/536 page Next 12345 下5页 Last page